Literature DB >> 32548693

CSCO breast cancer guideline: precise, economical and oriental.

Qian Li1,2, Jieqiong Liu1,2, Zefei Jiang3, Qiang Liu4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32548693     DOI： 10.1007/s11427-020-1701-5

Source DB:  PubMed          Journal:  Sci China Life Sci        ISSN： 1674-7305            Impact factor:   6.038


× No keyword cloud information.
  7 in total

1.  Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors.

Authors:  Zijie Cai; Jingru Wang; Yudong Li; Qianfeng Shi; Liang Jin; Shunying Li; Mengdi Zhu; Qi Wang; Lok Lam Wong; Wang Yang; Hongna Lai; Chang Gong; Yandan Yao; Yujie Liu; Jun Zhang; Herui Yao; Qiang Liu
Journal:  Sci China Life Sci       Date:  2022-08-11       Impact factor: 10.372

2.  Construction of Nomograms for Predicting Pathological Complete Response and Tumor Shrinkage Size in Breast Cancer.

Authors:  Shuai Yan; Wenjie Wang; Bifa Zhu; Xixi Pan; Xiaoyan Wu; Weiyang Tao
Journal:  Cancer Manag Res       Date:  2020-09-10       Impact factor: 3.989

3.  Expression of yes-associated protein, β-catenin and smoothened, and their clinical significance in invasive breast cancer.

Authors:  Pengju Liu; Jianfeng Zeng; Gaohua Yang
Journal:  Exp Ther Med       Date:  2022-05-06       Impact factor: 2.751

4.  MST1 inhibits the progression of breast cancer by regulating the Hippo signaling pathway and may serve as a prognostic biomarker.

Authors:  Xiang Jin; Lihua Zhu; Sheng Xiao; Zhuhong Cui; Jing Tang; Jiangyong Yu; Mingjun Xie
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

5.  Prognostic factors of primary neuroendocrine breast cancer: A population-based study.

Authors:  Shu-Tao Ma; Ding-Yuan Wang; Yi-Bing Liu; Hui-Jing Tan; Yue-Yue Ge; Yihebali Chi; Bai-Lin Zhang
Journal:  Cancer Med       Date:  2022-05-02       Impact factor: 4.711

6.  Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer.

Authors:  Xueying Wu; Chenyang Zhang; Henghui Zhang
Journal:  Curr Oncol       Date:  2022-01-10       Impact factor: 3.677

7.  Cancer-Specific Survival Outcome in Early-Stage Young Breast Cancer: Evidence From the SEER Database Analysis.

Authors:  Rui Liu; Zhesi Xiao; Daixing Hu; Haojun Luo; Guobing Yin; Yang Feng; Yu Min
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-18       Impact factor: 5.555
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.